Ann: Phase 2 trial shows significant improvements in Angelman, page-75

Fantastic results this morning and a great opportunity given the market prioritisation of a minor miss on royalty revenues. I've worked in drug design research and the trend has been towards precision medicine with drugs being more targeted and specific with a resulting decrease in the target population. What Neuren has here in 2591 as a platform therapy based on modulation of IGF-1 levels is astounding. The biggest issue right now would be that these are small open label Phase 2 trials but as somewhat of a counter there is Daybue which although not working in the same way, does provide an on market success story of how IGF-1 modulation can achieve real world outcomes in patients. None of this will be lost on the brains at Big Pharma and all we need right now is for two or more to want in and know they can't just sit back and wait. I still think the FDA meeting is something they'll wait for but then by Q4 I'd be very surprised if there hasn't been some genuine takeover talk